KR102323515B1 - 아자-피리돈 화합물 및 이의 용도 - Google Patents

아자-피리돈 화합물 및 이의 용도 Download PDF

Info

Publication number
KR102323515B1
KR102323515B1 KR1020167009194A KR20167009194A KR102323515B1 KR 102323515 B1 KR102323515 B1 KR 102323515B1 KR 1020167009194 A KR1020167009194 A KR 1020167009194A KR 20167009194 A KR20167009194 A KR 20167009194A KR 102323515 B1 KR102323515 B1 KR 102323515B1
Authority
KR
South Korea
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167009194A
Other languages
English (en)
Korean (ko)
Other versions
KR20160052715A (ko
Inventor
레오니드 베이겔만
데이빗 버나드 스미스
안티샤 디미트로바 스토이체바
로버트 댄 헨드릭스
Original Assignee
얀센 바이오파마, 인코퍼레이트.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오파마, 인코퍼레이트. filed Critical 얀센 바이오파마, 인코퍼레이트.
Priority to KR1020217035836A priority Critical patent/KR102468319B1/ko
Publication of KR20160052715A publication Critical patent/KR20160052715A/ko
Application granted granted Critical
Publication of KR102323515B1 publication Critical patent/KR102323515B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167009194A 2013-09-12 2014-09-10 아자-피리돈 화합물 및 이의 용도 Expired - Fee Related KR102323515B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217035836A KR102468319B1 (ko) 2013-09-12 2014-09-10 아자-피리돈 화합물 및 이의 용도

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361877151P 2013-09-12 2013-09-12
US61/877,151 2013-09-12
US201462011784P 2014-06-13 2014-06-13
US62/011,784 2014-06-13
US201462031673P 2014-07-31 2014-07-31
US62/031,673 2014-07-31
PCT/US2014/055012 WO2015038655A1 (en) 2013-09-12 2014-09-10 Aza-pyridone compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217035836A Division KR102468319B1 (ko) 2013-09-12 2014-09-10 아자-피리돈 화합물 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20160052715A KR20160052715A (ko) 2016-05-12
KR102323515B1 true KR102323515B1 (ko) 2021-11-05

Family

ID=52626171

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167009194A Expired - Fee Related KR102323515B1 (ko) 2013-09-12 2014-09-10 아자-피리돈 화합물 및 이의 용도
KR1020217035836A Active KR102468319B1 (ko) 2013-09-12 2014-09-10 아자-피리돈 화합물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217035836A Active KR102468319B1 (ko) 2013-09-12 2014-09-10 아자-피리돈 화합물 및 이의 용도

Country Status (18)

Country Link
US (5) US9328119B2 (https=)
EP (2) EP3778603A1 (https=)
JP (1) JP6448647B2 (https=)
KR (2) KR102323515B1 (https=)
CN (1) CN105764904B (https=)
AU (2) AU2014318832B2 (https=)
BR (1) BR112016005270B1 (https=)
CA (1) CA2923075C (https=)
CL (1) CL2016000539A1 (https=)
EA (1) EA037949B1 (https=)
ES (1) ES2821394T3 (https=)
IL (2) IL244432B (https=)
MX (2) MX377396B (https=)
PE (1) PE20160661A1 (https=)
PH (1) PH12016500486A1 (https=)
TW (1) TWI652269B (https=)
UA (1) UA121199C2 (https=)
WO (1) WO2015038655A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015038655A1 (en) * 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
ES2724581T3 (es) 2013-09-12 2019-09-12 Janssen Biopharma Inc Compuestos de piridazinona y usos de los mismos
WO2016145103A1 (en) * 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
MX394421B (es) 2015-04-28 2025-03-24 Shionogi & Co Derivados de piridona policiclica sustituida y profarmaco de los mismos
BR112017022550B1 (pt) 2015-04-28 2021-02-23 Shionogi & Co., Ltd derivados policíclicos de piridona substituída
JP6857617B2 (ja) * 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
AU2016374416A1 (en) 2015-12-15 2018-06-14 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017156407A1 (en) * 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
RU2727962C1 (ru) 2016-08-10 2020-07-28 Сионоги Энд Ко., Лтд. Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN111848615B (zh) * 2018-01-17 2022-05-17 江西彩石医药科技有限公司 吡啶酮衍生物及包含其的抗流感病毒药物组合物
KR20230031990A (ko) 2018-02-28 2023-03-07 노파르티스 아게 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물
CN113286793B (zh) * 2018-09-10 2024-04-05 共结晶制药公司 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
EP4121031A4 (en) 2020-03-20 2024-03-27 Atux Iskay LLC 3-DIARYLMETHYLENE AND THEIR USE
US20230290957A1 (en) 2020-12-14 2023-09-14 The School Corporation Kansai University Electrode for electrochemical device and non-aqueous electrolyte secondary battery
CN117126044B (zh) * 2023-04-12 2024-01-26 延边大学 一种微波辅助的甲基酮类化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM354694A0 (en) * 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN100357284C (zh) * 2003-09-11 2007-12-26 浙江海正药业股份有限公司 抗流感病毒化合物及其制备方法和用途
WO2005087766A1 (en) * 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005099699A1 (en) 2004-04-07 2005-10-27 Sepracor Inc. Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
WO2006028963A2 (en) 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
ZA200805191B (en) * 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
KR20090097194A (ko) 2006-12-22 2009-09-15 아벡사 리미티드 바이사이클 피리미디논 및 그 용도
FR2921505B1 (fr) 2007-09-25 2014-01-31 Alstom Transport Sa Dispositif de communication radioelectrique
JP2009096991A (ja) 2007-09-27 2009-05-07 Fujifilm Corp 硬化性組成物、画像形成材料及び平版印刷版原版
WO2009053799A1 (en) 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2010080864A1 (en) 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
NZ594851A (en) 2009-02-05 2013-10-25 Takeda Pharmaceutical Pyridazinone compounds
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
LT2444400T (lt) * 2009-06-15 2018-06-11 Shionogi & Co., Ltd. Pakeistasis policiklinis karbamoilpiridono darinys
US8383638B2 (en) 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
PE20130010A1 (es) * 2010-02-26 2013-02-05 Japan Tobacco Inc Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012009194A1 (en) 2010-07-12 2012-01-19 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
MX2013003139A (es) 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.
HK1199028A1 (en) 2011-09-30 2015-06-19 Kineta, Inc. Anti-viral compounds
CN104918942A (zh) 2013-01-08 2015-09-16 萨维拉制药有限公司 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途
ES2724581T3 (es) 2013-09-12 2019-09-12 Janssen Biopharma Inc Compuestos de piridazinona y usos de los mismos
WO2015038655A1 (en) * 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CR20160557A (es) 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
WO2016145103A1 (en) * 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو

Also Published As

Publication number Publication date
JP6448647B2 (ja) 2019-01-09
NZ717591A (en) 2021-10-29
US20160228438A1 (en) 2016-08-11
IL244432A0 (en) 2016-04-21
EP3030566B1 (en) 2020-07-08
IL244432B (en) 2020-05-31
JP2016530314A (ja) 2016-09-29
EP3030566A1 (en) 2016-06-15
AU2014318832A1 (en) 2016-04-28
US20210186969A1 (en) 2021-06-24
AU2019201403A1 (en) 2019-03-21
US20190314373A1 (en) 2019-10-17
ES2821394T8 (es) 2021-05-12
IL274355A (en) 2020-06-30
BR112016005270A2 (pt) 2017-12-12
CN105764904B (zh) 2020-02-11
HK1225715A1 (en) 2017-09-15
WO2015038655A1 (en) 2015-03-19
US20150072982A1 (en) 2015-03-12
US10702523B2 (en) 2020-07-07
US10251882B2 (en) 2019-04-09
KR20210135359A (ko) 2021-11-12
KR20160052715A (ko) 2016-05-12
US9328119B2 (en) 2016-05-03
TW201542553A (zh) 2015-11-16
MX377396B (es) 2025-03-10
EA201690372A1 (ru) 2016-08-31
EA037949B1 (ru) 2021-06-10
PH12016500486A1 (en) 2016-05-16
MX2016003199A (es) 2016-06-02
CA2923075C (en) 2022-07-26
AU2014318832B2 (en) 2018-11-29
AU2019201403B2 (en) 2021-01-21
US20200030328A1 (en) 2020-01-30
EP3778603A1 (en) 2021-02-17
EP3030566A4 (en) 2017-03-22
UA121199C2 (uk) 2020-04-27
CN105764904A (zh) 2016-07-13
TWI652269B (zh) 2019-03-01
CL2016000539A1 (es) 2016-09-02
US10980805B2 (en) 2021-04-20
CA2923075A1 (en) 2015-03-19
IL274355B (en) 2021-02-28
ES2821394T3 (es) 2021-04-26
PE20160661A1 (es) 2016-08-05
MX2020012132A (es) 2021-01-29
BR112016005270B1 (pt) 2022-11-01
KR102468319B1 (ko) 2022-11-16

Similar Documents

Publication Publication Date Title
KR102323515B1 (ko) 아자-피리돈 화합물 및 이의 용도
KR102286860B1 (ko) 피리다지논 화합물 및 이의 용도
AU2016229147C1 (en) Aza-pyridone compounds and uses thereof
HK40045896A (en) 7,8-dihydro-3h-pyrazino[1,2-b]pyridazine-3,5(6h)-dione compounds and uses thereof
HK1225715B (en) 7,8-dihydro-3h-pyrazino[1,2-b]pyridazine-3,5(6h)-dione compounds and uses thereof
NZ717591B2 (en) Aza-pyridone compounds and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241103

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241103

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241103